Related Experiment Video
Updated: Jul 8, 2026

Isolation and Preparation of Bacterial Cell Walls for Compositional Analysis by Ultra Performance Liquid Chromatography
Published on: January 15, 2014
Isolation and characterization of process related impurities and degradation products of bicalutamide and development
R Nageswara Rao1, A Narasa Raju, R Narsimha
1Analytical Chemistry Division, Discovery Laboratory, Indian Institute of Chemical Technology, Hyderabad 500007, India. rnrao55@yahoo.com
Abstract:
A reversed-phase high-performance liquid chromatographic method was developed for determination of process impurities and degradation products of bicalutamide in bulk drug and pharmaceutical formulations. The separation was accomplished on a Symmetry C(18) (4.6 mm x 250 mm; particle size 5 microm) column under isocratic mode. The mobile phase was 0.01 M KH(2)PO(4) (pH 3.0):acetonitrile (50:50 v/v) and a PDA detector set at 215 nm was used for detection. Forced degradation of bicalutamide was carried out under thermal, photo, acidic, alkaline and peroxide conditions. The unknown process impurities and alkaline degradation products were isolated and characterized by ESI-MS/MS, (1)H NMR and FT-IR spectral data. Under alkaline conditions bicalutamide was degraded in to an acid and an amine. The kinetics of degradation was studied. The proposed method was validated and successfully applied to the analysis of commercial formulations. Thus, the developed method can be used for process development as well as quality assurance of bicalutamide in bulk drug and pharmaceutical formulations.
More Related Videos
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11:17Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
Related Concept Videos
High-Performance Liquid Chromatography: Elution Process
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence